74 related articles for article (PubMed ID: 38102535)
1. A real-world prospective observational study of eptinezumab in Asian patients with migraine.
Zhao YJ; Ong JJY; Sonu SK; Dang J; Ng CC; Herr KJ; Bose R; Jion YI
Headache; 2024 May; ():. PubMed ID: 38785386
[TBL] [Abstract][Full Text] [Related]
2. Eptinezumab Demonstrated Efficacy Regardless of Prior Preventive Migraine Treatment Failure Type: Post Hoc Analyses of the DELIVER Study.
Pozo-Rosich P; Ashina M; Tepper SJ; Jensen S; Boserup LP; Josiassen MK; Sperling B
Neurol Ther; 2024 Apr; 13(2):339-353. PubMed ID: 38236314
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 3 Treatment Strategies for Medication Overuse Headache: A Randomized Clinical Trial.
Carlsen LN; Munksgaard SB; Nielsen M; Engelstoft IMS; Westergaard ML; Bendtsen L; Jensen RH
JAMA Neurol; 2020 Sep; 77(9):1069-1078. PubMed ID: 32453406
[TBL] [Abstract][Full Text] [Related]
4. Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review.
Irimia P; Santos-Lasaosa S; Pozo-Rosich P; Leira R; Pascual J; Láinez JM
Front Neurol; 2024; 15():1355877. PubMed ID: 38523607
[TBL] [Abstract][Full Text] [Related]
5. Lipopolysaccharide, VE-cadherin, HMGB1, and HIF-1α levels are elevated in the systemic circulation in chronic migraine patients with medication overuse headache: evidence of leaky gut and inflammation.
Vuralli D; Ceren Akgor M; Gok Dagidir H; Gulbahar O; Yalinay M; Bolay H
J Headache Pain; 2024 Feb; 25(1):23. PubMed ID: 38369488
[TBL] [Abstract][Full Text] [Related]
6. Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Imai N; Isogai Y; Shibasaki Y; Nakai M; Ishida M; Ning X; Koga N
Neurol Ther; 2023 Dec; 12(6):1981-1991. PubMed ID: 37695442
[TBL] [Abstract][Full Text] [Related]
7. An economic evaluation of eptinezumab for the preventive treatment of migraine in the UK, with consideration for natural history and work productivity.
Griffin E; Shirley G; Lee XY; Awad SF; Tyagi A; Goadsby PJ
J Headache Pain; 2024 Apr; 25(1):59. PubMed ID: 38637754
[TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness and satisfaction with intravenous eptinezumab treatment in patients with chronic migraine: REVIEW, an observational, multi-site, US-based study.
Argoff C; Herzog SP; Smith RM; Kotak SV; Sopina L; Saltarska Y; Soni-Brahmbhatt S; Khan FA
J Headache Pain; 2024 Apr; 25(1):65. PubMed ID: 38664605
[TBL] [Abstract][Full Text] [Related]
9. Structural equation modeling for identifying the drivers of health-related quality of life improvement experienced by patients with migraine receiving eptinezumab.
Jönsson L; Awad SF; Regnier SA; Talon B; Kymes S; Lee XY; Goadsby PJ
J Headache Pain; 2024 Mar; 25(1):45. PubMed ID: 38549121
[TBL] [Abstract][Full Text] [Related]
10. Medication-Overuse Headache: Differences between Daily and Near-Daily Headache Patients.
Krymchantowski AV; Tepper SJ; Jevoux C; Valença MM
Brain Sci; 2016 Aug; 6(3):. PubMed ID: 27537917
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of eptinezumab 300mg versus 100mg for migraine patients: a meta-analysis of randomized controlled studies.
Chen H; Luo W
Int J Neurosci; 2024 May; 134(5):462-467. PubMed ID: 35993143
[No Abstract] [Full Text] [Related]
12. CandeSpartan Study: Candesartan Spanish Response-prediction and Tolerability study in migraine.
García-Azorín D; Martínez-Badillo C; Camiña Muñiz J; Gago-Veiga AB; Morollón Sánchez N; González-Quintanilla V; Porta-Etessam J; Sierra-Mencía A; González-García N; González-Osorio Y; Polanco-Fernandez M; Recio-García A; Belvis Nieto R; Guerrero-Peral AL
Cephalalgia; 2024 Apr; 44(4):3331024241248833. PubMed ID: 38663908
[TBL] [Abstract][Full Text] [Related]
13. Effects of electroacupuncture on treatment-resistant chronic migraine with medication overuse headache: A 12-month follow-up case report.
Gao N; Wu L; Liu X; Lin Z; Liu Z; Liang J; Wang W
Heliyon; 2024 May; 10(9):e30417. PubMed ID: 38720738
[TBL] [Abstract][Full Text] [Related]
14. Medication overuse headache: a critical review of end points in recent follow-up studies.
Hagen K; Jensen R; Bøe MG; Stovner LJ
J Headache Pain; 2010 Oct; 11(5):373-7. PubMed ID: 20473701
[TBL] [Abstract][Full Text] [Related]
15. Medication-overuse headache: a narrative review.
Gosalia H; Moreno-Ajona D; Goadsby PJ
J Headache Pain; 2024 May; 25(1):89. PubMed ID: 38816828
[TBL] [Abstract][Full Text] [Related]
16. Migraine classification by machine learning with functional near-infrared spectroscopy during the mental arithmetic task.
Chen WT; Hsieh CY; Liu YH; Cheong PL; Wang YM; Sun CW
Sci Rep; 2022 Aug; 12(1):14590. PubMed ID: 36028633
[TBL] [Abstract][Full Text] [Related]
17. To treat or not to treat? Medication underuse headache, a novel reframing.
Sandoe CH; Becker WJ
Cephalalgia; 2024 May; 44(5):3331024241252159. PubMed ID: 38735058
[No Abstract] [Full Text] [Related]
18. Protective Effects of β-Blockers on Bone in Older Adults with Dementia.
Khuc K; des Bordes J; Ogunwale A; Madel MB; Ambrose C; Schulz P; Elefteriou F; Schwartz A; Rianon NJ
Calcif Tissue Int; 2024 Jul; 115(1):14-22. PubMed ID: 38744723
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of eptinezumab in patients with chronic migraine and medication-overuse headache: a randomized, double-blind, placebo-controlled study.
Yu S; Zhou J; Luo G; Xiao Z; Ettrup A; Jansson G; Florea I; Ranc K; Pozo-Rosich P
BMC Neurol; 2023 Dec; 23(1):441. PubMed ID: 38102535
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
